Related Experiment Video

Updated: Nov 4, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.7K

Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study

Antonia Anna Lukito1, Allen Widysanto2, Theo Audi Yanto Lemuel2

  • 1Medical Science Group Team, Tangerang, Indonesia; Pelita Harapan University, Tangerang, Indonesia; Siloam Hospitals, Tangerang, Indonesia; Mochtar Riady Institute of Nanotechnology, Tangerang, Indonesia.

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|May 26, 2021
PubMed

Insights

Candesartan treatment for COVID-19 patients significantly shortened hospital stays. In non-obese patients, candesartan also accelerated negative swabs and improved chest X-ray findings.

Area of Science:

  • Cardiovascular research
  • Infectious disease management
  • Clinical pharmacology

Background:

  • Investigating the efficacy of candesartan in hospitalized COVID-19 patients.
  • Assessing the impact of candesartan on clinical outcomes beyond standard care.

Purpose of the Study:

  • To determine if adding candesartan to standard care improves outcomes for COVID-19 patients.
  • Evaluating candesartan's effect on length of hospital stay, time to negative swab, and radiological improvement.

Main Methods:

  • Prospective, non-randomized, open-label study with 75 COVID-19 patients (aged 18-70).
  • Utilized uni- and multi-variable Cox regression analyses to calculate hazard ratios (HRs).
  • Primary outcomes included hospital stay duration, time to negative swab, and chest X-ray improvement.

Main Results:

  • Candesartan group showed a significantly shorter hospital stay (adjusted HR 2.47).
  • No increased risk of intensive care unit admission was observed.
  • In non-obese patients, candesartan accelerated time to negative swab (adjusted HR 2.40) and chest X-ray improvement (adjusted HR 2.82).

Conclusions:

  • Candesartan significantly reduces hospital stay duration in COVID-19 patients, even after covariate adjustment.
  • Significant improvements in primary outcomes were observed in the non-obese subgroup treated with candesartan.
Abstract

Keywords:
AngiotensinCandesartanCoronavirusSARS-CoV-2Severity

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

432
Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.0K

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
640
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
966
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
266
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
1.9K